ANGLE plc’s £20 Million Placing

In UK Hill Dickinson, advised on the matter.

Hill Dickinson advised FinnCap Ltd, WG Partners with a team including Ian Gillis (Picture – Equity Capital Markets).

ANGLE plc is an industry leading developer of liquid biopsy testing for the purpose of identifying cancer cells by way of blood test, as opposed to invasive excision and biopsy testing.

ANGLE plc is currently in the process of obtaining US FDA approval for its Parsortix® testing, which would be the first such approval granted by the FDA. 

The proceeds of the fundraising will be used to pursue additional opportunities for the development of ANGLE plc healthtech, including the development of pre-biopsy testing for prostate cancer, as well as strengthening its existing testing and pharma service offerings. 

The Hill Dickinson team comprised Ian Gillis (Picture), partner, Katie Somerville, senior associate, and Oli Benson, paralegal.

Involved fees earner: Ian Gillis – Hill Dickinson; Katie Somerville – Hill Dickinson;

Law Firms: Hill Dickinson;

Clients: FinnCap Ltd; WG Partners;

Author: Giulia Di Palma